檢索結果 - Trishna Goswami

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

    Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous c... 由 Jill Gilbert, Christophe Le Tourneau, Hisham Mehanna, Jérôme Fayette, Trishna Goswami, Ugochi Emeribe, Anthony Jarkowski, Giovanni Melillo, L.L. Siu

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

    Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous... 由 Robert L. Ferris, C. Even, Robert Haddad, Makoto Tahara, Trishna Goswami, April Franks, Ugochi Emeribe, Anthony Jarkowski, Giovanni Melillo, Lisa Licitra

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

    Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial 由 Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhi... 由 Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket tria... 由 Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: